Aptar Pharma touts FDA approval of nasal spray device

Aptar Pharma said this week that its Bidose nasal spray device won FDA approval for use with a breakthrough depression therapy.
The Crystal Lake, Ill.-based company’s Bidose tech enables two-shot nasal drug delivery. Aptar touted its manufacturing facility in Congers, NY, which supports the manufacture of nasal and injectable drug delivery systems.
Get the full story at our sister site, Drug Delivery Business News.
The post Aptar Pharma touts FDA approval of nasal spray device appeared first on MassDevice.

Source: Mass Device - March 19, 2019 Category: Medical Devices Authors: Sarah Faulkner Tags: Drug-Device Combinations Food & Drug Administration (FDA) Neurological Pharmaceuticals aptarpharma Source Type: news